Harnessing the MYB-dependent TAL1 5'super-enhancer for targeted therapy in T-ALL.
Smith C, Touzart A, Simonin M, Tran-Quang C, Hypolite G, Latiri M, Andrieu GP, Balducci E, Dourthe MÉ, Goyal A, Huguet F, Petit A, Ifrah N, Baruchel A, Dombret H, Macintyre E, Plass C, Ghysdael J, Boissel N, Asnafi V.
Smith C, et al. Among authors: goyal a.
Mol Cancer. 2023 Jan 18;22(1):12. doi: 10.1186/s12943-022-01701-x.
Mol Cancer. 2023.
PMID: 36650499
Free PMC article.